国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

您現(xiàn)在的位置: > Language Tips > Audio & Video > Special Speed News  
 





  Once-daily pill could simplify HIV treatment
[ 2006-02-06 15:57 ]


I’m Steve Ember with the VOA Special English Health Report.


Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

Experts say more than forty million people around the world are living with H.I.V.

This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

Vocabulary

 

 

 
 
 




同心县| 平凉市| 定边县| 阿合奇县| 丰原市| 班戈县| 隆子县| 平江县| 蓬安县| 广昌县| 淮安市| 抚远县| 专栏| 和平县| 顺义区| 宝兴县| 牙克石市| 镇坪县| 响水县| 宜君县| 大石桥市| 麦盖提县| 当涂县| 东源县| 吴堡县| 新乐市| 义乌市| 万山特区| 晋州市| 萝北县| 新龙县| 体育| 惠州市| 黑水县| 塔城市| 东乌珠穆沁旗| 樟树市| 开平市| 阿克| 右玉县| 鄂伦春自治旗|